ACMD Consumer CBD Products: call for evidence

  • by

ACMD has been commissioned to provide impartial and independent scientific advice on the acceptable levels of constituent cannabinoids in CBD products marketed as consumer products. In this member event ACI will gather input from our members for our response.

Update on Development of FSA’s Public List

  • by

On Friday 26 March 2021, ACI representatives met with the FSA for clarification relating to the novel foods validation process and the publication of the list that they mentioned in their update on 12 March.

ACI and CMC Recommend Home Office Clarifies THC Limits for CBD Products

  • by

Experts from the Association for the Cannabinoid Industry (ACI) and Centre for Medicinal Cannabis (CMC) have put together a detailed safety review paper of THC – Health Guidance Levels for THC in CBD products: Safety Assessment & Regulatory Recommendations. The paper recommends further research and makes policy recommendations.